# Corteria Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corteria-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.corteriapharma.com
- Total disclosed funding: $79M
- Latest round: Series A (Sep 4, 2023)
- Investors on record: 7

## About

Corteria Pharmaceuticals, based in France, focuses on developing innovative therapeutics for critical medical conditions such as heart failure, sarcopenia, and obesity-related complications to improve patient outcomes.Founded in 2021 and headquartered in Paris, France, Corteria Pharmaceuticals is dedicated to advancing novel therapeutics. The company successfully completed 4 deals, with its most recent funding round being a Series A that raised EUR 65.00 mn on September 4, 2023, led by Jeito Capital and OrbiMed Advisors, along with several other investors. The firm was established as a standalone entity and has not undergone any notable pivots in its business strategy since inception.Corteria Pharmaceuticals specializes in developing innovative therapeutics aimed at addressing critical unmet medical needs in conditions such as worsening heart failure, sarcopenia, and obesity-related complications. Their primary products COR-1167 and COR-1389 target specific biological pathways involved in fluid retention and cardiac function. The company utilizes methodologies for patient stratification to ensure effective treatment delivery. Their primary markets include North America and Europe, targeting healthcare providers, hospitals, and clinics managing patients with these conditions.Corteria Pharmaceuticals generates revenue through strategic partnerships and collaborations with healthcare institutions and research organizations. Their business model relies on securing agreements for clinical trial phases, which include milestone payments tied to clinical development stages and potential royalties from future product sales. Their flagship products COR-1167 and COR-1389 are incorporated into treatment regimens offered by healthcare providers to patients experiencing acute and chronic heart failure episodes.In September 2023, Corteria Pharmaceuticals raised EUR 65.00 mn in Series A funding, co-led by Jeito Capital and OrbiMed Advisors, aimed at supporting the development of their medicines for cardiovascular diseases. The company plans to utilize this funding to enhance their product pipeline and expand into new markets, specifically targeting regions with high incidences of cardiovascular issues. They are focused on rolling out new therapies based on their current innovations in the coming years.

## Funding rounds

- Series A, Sep 4, 2023, $70M — OrbiMed Advisors, Omnes Capital, Fountain Healthcare Partners, Kurma Partners, V-Bio Ventures, Invivo Partners, Jeito Capital
- Series A, Sep 8, 2021, $6.8M — Omnes Capital, Fountain Healthcare Partners, Kurma Partners, V-Bio Ventures, Invivo Partners
- Series A, Jun 4, 2021, $1.8M — Kurma Partners

## Investors

- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series A
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A
- Invivo Partners (https://capitalatlas.ai/funds/invivo-partners) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A